Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 76 Show results per page	View Search Criteria \| Help With Results

	Title				Phase				Protocol IDs

	Docetaxel With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer				Phase III				ECOG-E1302 E1302, NCT00088907
	Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer (Paradigm Trial)				Phase III				DFCI-04006 AVENTIS-DFCI-04006, NCT00095875, PARADIGM TRIAL
	Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)				Phase III				IRB 13362B NCT00117572
	Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer				Phase III				RTOG-0522 RTOG 0522, RTOG-0522, NCT00265941
	Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery				Phase III				EGF102988 NCT00424255
	Radiation Therapy and Cisplatin With or Without Fluorouracil in Treating Patients With Stage III or Stage IV Head and Neck Cancer				Phase III				CASE-3307-CC389 CASE-3307, CASE-CC389, CASE3307-CC389, NCT00608205
	Nutrition and Resistance Training in Head and Neck Cancer				Phase III				080219 NCT00696553
	Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer (Paradigm Trial)				Phase III				0120070101 NCT00705068
	Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer				Phase II, Phase I				7077 NCT00140556
	Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer				Phase II, Phase I				Hx-EGFr-203 NCT00401401


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute